Tango Presents Promising Results from Phase 1/2 Study of Vopimetostat and Daraxonrasib in Pancreatic Cancer and Provides Updates to Development Strategy

Vopimetostat plus daraxonrasib produced an 82% objective response rate in patients with second- or third-line pancreatic cancer. Median progression-free survival had not yet been reached, and the 9-month PFS rate was 88%; the brief report provides no comparator or additional trial details.